So far it looks like Takeda is going to swallow Shire. A great deal of their products are hemophilia related. Why would Takeda be interested in paying money for hemophilia stuff? Do you think they will sell off their hemophilia division after the deal is done?
Takeda will probably license out the drugs to Pfizer or Boeringer since they can’t seem to actually own their entire portfolio and grow the company the way a proper pharma company does.
Was a total money maker. Takeda paid way too much for Shire. https://www.investors.com/news/technology/roche-hemophilia-treatment-hemlibra-shire/
Very true! * Hem franchise is smoke and mirrors. Roche will destroy with Hemlibra. * Neuro is old and a joke anymore. Primary care. Sales could be maintained with 1/10 the current sales force. * Oph franchise is a failure at best. WAY overpriced eye drops that aren’t covered on a majority of plans. Primary care. * immunology franchise is a ? at best. Per the norm at shire, the current l’ship team is a train wreck. Heavy competition in HAE for a rare drug, sales in US for new product will be hurt by also launching subq cinryze. Ex-us sales challenging based on reimbursement (read: low prices). * GI franchise trying to sell incredibly challenging drugs with poor reimbursement and a crowded space with no understanding of how a rare disease mkt works consistent themes at shire: * for all the attempts to say shire is a rare disease company, they have NO IDEA how to run rare businesses. Look at senior leadership: none of them have experience in rare and it shows. They don’t understand the differences between primary care and rare. Immunology is a great example: the fate of shire hinges on a very successful launch of lanadelumab. The problem: head of franchise is clueless. Spent a little while as Fleming’s chief of staff, then ran the nordics into the ground (with massive turnover), and is now head of immunology. His proudest accomplishment is making the sales force do 5 calls/day. Head of sales is literally the dumbest person ever. (Think about the movie clueless and that is spot on) * turnover rates are through the roof * sales force in each franchise is highly disengaged. * revenue increases are due more to price increases than sales increases. It’s all about stocking/destocking. * leadership couldn’t possibly be worse. VP level and above literally are ALL there by cronyism, except for Neuro who is in there by nepotism. ALL good leadership has bailed. The problem with that: the strategic decisions being made are all based on getting the company sold. Short term vision. * pipeline is grossly overexaggerated. In other words, Takeda is (very foolishly) acquiring a company on its last legs, where anyone with a brain has already left or is trying to leave. This will definitely come to be known as the worst corporate acquisition in the history of biotech and will mark the beginning of the end of Takeda. Shire senior leadership is licking their chops. They can’t wait to unload this lemon on an unsuspecting Takeda.
62 billion dollar acquisition’s Aren’t taken lightly, Takeda is a solid company, very happy to be a rep here. This a bunch of salty shire reps venting bc they know they are done once the deal goes through?
Anyone know what the pricing of Lanadelumab might look like?? Will it be more expensive than HAegarda?
Takeda is not a solid company in the US. GenMed is a joke and they are all just waiting to be laid off. Specialty is one drug Entyvio, which has been a revolving door in hom office leadership for years. Want to transfer to Takeda oncology, you have to quit GenMed/Specialty. Takeda oncology doesn’t even talk to their partners in the other BUs.
